Literature DB >> 25270719

[Myocardial ischemia caused by overuse of headache medications].

T Kraya1, A Schlitt.   

Abstract

Myocardial infarction as the most severe clinical manifestation of coronary atherosclerosis is the major cause of death in western countries. Although rupture of an atherosclerotic plaque is generally causal for this event, in recent years differential diagnoses have been discussed to further optimize diagnosis and treatment of myocardial ischemia. The "universal definition of myocardial infarction" defines five subtypes of myocardial infarction: in particular, type 2 myocardial infarction includes other diseases related to myocardial ischemia such as hyper- or hypotension, coronary artery spasms, arrhythmia, etc. Some medications for the acute therapy of migraine like triptans can lead to myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25270719     DOI: 10.1007/s00063-014-0421-9

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  17 in total

Review 1.  Sumatriptan therapy for headache and acute myocardial infarction.

Authors:  Silvia Barra; Simona Lanero; Alfredo Madrid; Crescenzo Materazzi; Giancarlo Vitagliano; Paul R J Ames; Giovanni Gaeta
Journal:  Expert Opin Pharmacother       Date:  2010-11       Impact factor: 3.889

2.  Detoxification for medication overuse headache is the primary task.

Authors:  Jes Olesen
Journal:  Cephalalgia       Date:  2011-12-15       Impact factor: 6.292

3.  The International Classification of Headache Disorders, 3rd edition (beta version).

Authors: 
Journal:  Cephalalgia       Date:  2013-07       Impact factor: 6.292

Review 4.  Side effects of cocaine abuse: multiorgan toxicity and pathological consequences.

Authors:  I Riezzo; C Fiore; D De Carlo; N Pascale; M Neri; E Turillazzi; V Fineschi
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  Acute myocardial infarction during regadenoson myocardial perfusion imaging.

Authors:  Sachil Shah; David Parra; Robert S Rosenstein
Journal:  Pharmacotherapy       Date:  2013-03-07       Impact factor: 4.705

6.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

Review 7.  Coronary artery spasm--clinical features, diagnosis, pathogenesis, and treatment.

Authors:  Hirofumi Yasue; Hitoshi Nakagawa; Teruhiko Itoh; Eisaku Harada; Yuji Mizuno
Journal:  J Cardiol       Date:  2008-02-01       Impact factor: 3.159

8.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

9.  Coronary side-effect potential of current and prospective antimigraine drugs.

Authors:  A MaassenVanDenBrink; M Reekers; W A Bax; M D Ferrari; P R Saxena
Journal:  Circulation       Date:  1998-07-07       Impact factor: 29.690

10.  Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.

Authors:  S Lugardon; H Roussel; V Sciortino; J L Montastruc; M Lapeyre-Mestre
Journal:  Eur J Clin Pharmacol       Date:  2007-06-19       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.